{"analyses":[{"ciLowerLimit":"0.35","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.56","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.44","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.36","ciPctValue":"95","ciUpperLimit":"0.64","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.48","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.77","upperLimit":"9.10","value":"8.31"},{"groupId":"OG001","lowerLimit":"4.04","upperLimit":"4.44","value":"4.17"},{"groupId":"OG002","lowerLimit":"5.55","upperLimit":"8.41","value":"6.28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"131"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization until the date of objective disease progression or death, whichever came first, as assessed by BICR according to RECIST version 1.1. Progressed disease: Sum of diameters increased by greater than or equal to (\\>=)20 percent (%) and \\>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).","dispersionType":"95% Confidence Interval","groups":[{"description":"LACP dosing (study start until 6 November 2022): Participants received Lazertinib 240 milligrams (mg) orally on Day 1 of each subsequent cycle, starting with Cycle 3, along with Amivantamab 1400 mg (1750 mg if body weight greater than or equal to \\[\\>=80\\] kilograms \\[kg\\]) on Cycle 1 Days 1, 2, 8, and 15, and Cycle 2 Day 1 and 1750 mg (2100 mg if body weight \\>=80 kg). Participant also received Pemetrexed 500 mg per square meter (mg/m\\^2) on Day 1 21-day cycle, in combination with carboplatin 750 mg as IV infusion starting on Cycle 1 Day 1 for 4 cycles. From cycle 5 onwards, participants received Amivantamab, Pemetrexed and Lazertinib IV infusions at same dose, as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants received Amivantamab 1400 mg (1750 mg if body weight \\>=80\\] kg) on Cycle 1 Days 1,2, 8, and 15, and Cycle 2 Day 1 and 1750 mg (2100 mg if body weight \\>=80 kg). Participant also received Pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle, in combination with carboplatin 750 mg as IV infusion starting on Cycle 1 Day 1 for 4 cycles. Lazertinib 240 mg in ACP-L started on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4. From cycle 5 onwards, participants received Amivantamab, Pemetrexed and Lazertinib IV infusions at same dose, as maintenance until disease progression. Each cycle consists of 21 days.","id":"OG000","title":"Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)"},{"description":"Participants received Pemetrexed 500 mg/m\\^2 IV infusion and carboplatin 750 mg IV infusion from Day 1 of Cycle 1 to 4. From cycle 5 onwards, participants received Pemetrexed 500 mg/m\\^2 IV infusion, as maintenance until disease progression. Each cycle consists of 21 days.","id":"OG001","title":"Main Study: Arm B: Carboplatin + Pemetrexed (CP)"},{"description":"Participants received Amivantamab 1400 mg (1750 mg if body weight \\>=80 kg) on Cycle 1 Days 1,2, 8, and 15, and Cycle 2 Day 1 and 1750 mg (2100 mg if body weight \\>=80 kg) on Day 1 of each cycle, starting with Cycle 3. Participants also received Pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle, in combination with carboplatin 750 mg as IV infusion starting on Cycle 1 Day 1 for 4 cycles. From cycle 5 onwards, participants received Amivantamab and Pemetrexed IV infusions at same dose, as maintenance until disease progression. Each cycle consists of 21 days.","id":"OG002","title":"Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) as defined in the protocol included all randomized participants, classified according to their assigned treatment arm regardless of the actual treatment received. The outcomes reported here are for main study participants. For Arm A participants, data were planned to be analyzed as a single arm collectively for the LACP and ACP-L dosing regimens.","reportingStatus":"POSTED","timeFrame":"From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)","title":"Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)","type":"PRIMARY","unitOfMeasure":"months"}